Surrey Heartlands

Joint Formulary & PAD

Domperidone - Nausea and vomiting

You are here : Home > Formulary Search > Domperidone - Nausea and vomiting

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
ADULTS and adolescents over 12 years or weighing 35kg or more. Use lowest effective dose for shortest possible duration (max 1 week)
 

Status 2

Red
Formulations :
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
CHILDREN under 12 years: MHRA safet alert, In children younger than 12 years or patients weighing less than 35kg - restricted to secondary care for a duration of less than 1 week

Documentation

Evidence Review
Domperidone in N & V - Colour change document - March 2020.pdf

PAD Profile

ChemicalSubstance :
Domperidone
Indication :
Nausea and vomiting
Group Name :
Keywords :
Brand Names Include :
motilium
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Domperidone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Nausea and vomiting .

Committee Recommendations (1)

04 Mar 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommends the use of domperidone for the treatment of nausea and vomiting as follows:

  • GREEN - For relief of the symptoms of nausea and vomiting only in adults and adolescents 12 years of age or older and weighing 35kg or more. Domperidone should be used at the lowest effective dose for the shortest possible duration and maximum treatment duration should not usually exceed 1 week

 

  • RED - For any indications in children younger than 12 years or those weighing less than 35kg, only when prescribed within a secondary care setting and treatment duration should not exceed one week.

These changes are in line with the MHRA advice published in December 2019. Domperidone is no longer licensed for use in patients under 12 or those patients weighing less than 35kg. 

Prescribers should ensure that the patient/carer/legal guardian understands the risks and consents to using domperidone off-label noting the MHRA alert (updated 2019)

 MHRA Drug Safety Update, December 2019: https://www.gov.uk/drug-safety-update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children-reminder-of-contraindications-in-adults-and-adolescents

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication